ArticleIDCases2026
A rare invader on a cardiac stent:
Article in IDCases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Case summary: A 65-year-old man with diabetes, hypertension, and coronary artery disease developed persistent fever after PCI to the left anterior descending and right coronary arteries. Serial cardiac PET-CT and contrast-enhanced CT demonstrated a hypermetabolic middle mediastinal mass encasing the left main coronary artery and proximal branches, with a pseudoaneurysm arising from the proximal LAD. He underwent removal of the infected coronary stent, coronary artery bypass grafting, pericardiectomy, and biopsy/debridement of the mediastinal lesion. Tissue culture grew Intervention and outcome: The patient received a multidrug regimen anchored by amikacin and an oxazolidinone. Serum creatinine and audiometry were monitored for IV amikacin. Because of early hematologic intolerance to linezolid, therapy was transitioned to tedizolid 200 mg once daily, with clofazimine later used as the companion oral agent after intolerance to minocycline. The patient completed a total of 6 months of anti-NTM therapy, including approximately 5 months of tedizolid-based therapy. The follow-up monitoring sheets document stable hematological parameters and no peripheral neuropathy observed during the tedizolid phase. Serial imaging showed substantial regression of the mediastinal lesion without clinically significant FDG uptake at end of therapy. Conclusion: This case highlights three clinically relevant lessons: first, post-PCI
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.